
|Videos|March 23, 2011
Dr. Kris on the Crizotinib Clinical Trials
Author(s)Mark G. Kris, MD, FASCO
Dr. Mark G. Kris from Memorial Sloan-Kettering Cancer Center on the Crizotinib Clinical Trials
Advertisement
Mark G. Kris, MD, chief of the Thoracic Oncology Service at Memorial Sloan-Kettering Cancer Center, describes the goal in cancer care has been to know enough about cancer to find a characteristic that is a weakness to the cancer and exploit it.
When discussing the clinical trial Kris explains that only patients with an EML4-ALK translocation were allowed into the crizotinib clinical trial. He compares crizotinib to imatinib in BCR-ABL patients.
Advertisement
Advertisement
Advertisement
Trending on OncLive
1
Vopimetostat Plus Daraxonrasib Yields 92% ORR in MTAP-Deleted, RAS-Mutant Pancreatic Cancer
2
Subcutaneous Isatuximab Administered Via OBI Approved in EU for Multiple Myeloma
3
GU Cancer Experts Highlight the Most Impactful and Discussion-Worthy Data Presented at ASCO 2026
4
Dr Singh on Multidisciplinary Brain Tumor Management Strategies
5






































































